RPL13AP16: A Potential Drug Target and Biomarker (G100129553)

Target Name: RPL13AP16

NCBI ID: G100129553

RPL13AP16

Other Name(s): Ribosomal protein L13a pseudogene 16 | ribosomal protein L13a pseudogene 16 | RPL13A_7_832

RPL13AP16: A Potential Drug Target and Biomarker

Rpl13ap16 is a gene that encodes for a protein known as RPL13ap16. RPL13ap16 plays a critical role in the regulation of DNA replication in bacteria, and is a key component of the replication machinery. Mutations in the Rpl13ap16 gene have been linked to various genetic disorders, including microcephaly and Down syndrome.

In addition to its role in gene regulation, Rpl13ap16 has also been shown to have potential as a drug target. The protein encoded by Rpl13ap16 has been shown to interact with various drug molecules, including small molecules, peptides, and antibodies. This interaction suggests that Rpl13ap16 could be a target for drugs that are designed to modulate its function.

One potential mechanism by which Rpl13ap16 could be targeted by drugs is through its role in the regulation of DNA replication. Mutations in the Rpl13ap16 gene have been linked to alterations in the timing and efficiency of DNA replication. This could lead to a range of cellular and molecular changes, including increased or reduced replication efficiency, and changes in the structure and composition of the replicated DNA.

Drugs that are designed to modulate the function of Rpl13ap16 could potentially be used to treat a range of genetic disorders, including microcephaly and Down syndrome. For example, drugs that inhibit the activity of Rpl13ap16 could potentially be used to treat microcephaly by preventing the excessive replication of DNA that is responsible for the development of microcephaly. Similarly, drugs that enhance the activity of Rpl13ap16 could potentially be used to treat Down syndrome by increasing the efficiency of DNA replication in cells.

In addition to its potential as a drug target, Rpl13ap16 also has potential as a biomarker. The protein encoded by Rpl13ap16 is highly conserved across different bacterial species, which suggests that it is a reliable and robust marker for bacterial stocks. This could make Rpl13ap16 an attractive candidate for use as a biomarker in various medical applications, including the diagnosis and monitoring of bacterial infections.

Overall, Rpl13ap16 is a gene that has significant potential as a drug target and biomarker. Further research is needed to fully understand its function and to develop drugs that can modulate its activity. By further studies, researchers may be able to determine the most effective and safe ways to use Rpl13ap16 as a drug or biomarker, and to develop new treatments for a range of genetic disorders.

Protein Name: Ribosomal Protein L13a Pseudogene 16

The "RPL13AP16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets